- Arrowhead to receive ~$300M up front, ~$740M as development, regulatory and commercial milestones and is eligible to receive royalties of 20-25% on net sales
- If approved, the companies will co-develop ARO-AAT and co-commercialize it in the US, under 50/50 profit sharing structure. Additionally, Takeda will lead the global commercialization strategy and get an exclusive license to commercialize the therapy outside the US
- ARO-AAT is designed to knock down the hepatic production of the Z-AAT protein and is potential first-in-class therapy designed to treat the underlying cause of liver disease associated with AATD
Click here to read full press release/ article | Ref: Takeda | Image: Technology Networks
The post Takeda Signs ~B Pact with Arrowhead for ARO-AAT Targeting Alpha-1 Antitrypsin-Associated Liver Disease first appeared on PharmaShots.